Gina F. Adams
Known title: EVP GENL COUNSEL/SECTYCIK: 0001967230
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Entergy faces rate headwinds as analysts lower price targets. Entergy's solid data center and utility fundamentals are currently overshadowed by rate headwinds, prompting several firms to lower their price targets. JP Morgan, Keybanc, and Truist all maintained positive ratings but reduced their outlooks to $130, $118, and $119, respectively. These adjustments place the new targets below the stock's 52-week high of $118.45, signaling caution despite the company's ongoing sustainability and workforce initiatives.
Transaction History
| FDX | ▲ Buy | Grant | 4,734 | $0 | 6/25/2026 | View on chart |
| ETR | ▲ Buy | Grant | 858 | $0 | 6/1/2026 | View on chart |
| FDX | ▲ Buy | Option Exercise | 5,655 | $921K | 4/14/2026 | View on chart |
| FDX | ▲ Buy | Option Exercise | 7,085 | $1.1M | 4/14/2026 | View on chart |
| FDX | ▲ Buy | Option Exercise | 7,710 | $1.0M | 4/14/2026 | View on chart |
| FDX | ▼ Sell | Open Market | 14,015 | $5.1M | 4/14/2026 | View on chart |
| FDX | ▼ Sell | Open Market | 6,435 | $2.4M | 4/14/2026 | View on chart |
| ETR | ▲ Buy | Grant | 217 | $0 | 3/2/2026 | View on chart |
| ETR | ▲ Buy | Grant | 245 | $0 | 12/1/2025 | View on chart |
| ETR | ▲ Buy | Grant | 265 | $0 | 9/2/2025 | View on chart |
| FDX | ▲ Buy | Grant | 6,325 | $0 | 6/26/2025 | View on chart |
| ETR | ▲ Buy | Grant | 279 | $0 | 6/2/2025 | View on chart |
| ETR | ▲ Buy | Grant | 1,023 | $0 | 6/2/2025 | View on chart |
| FDX | ▲ Buy | Option Exercise | 4,770 | $863K | 3/24/2025 | View on chart |
| FDX | ▼ Sell | Open Market | 4,770 | $1.2M | 3/24/2025 | View on chart |
| ETR | ▲ Buy | Grant | 265 | $0 | 2/28/2025 | View on chart |
| FDX | ▼ Sell | Gift | 5,150 | $0 | 12/23/2024 | View on chart |
| ETR | ▲ Buy | Grant | 149 | $0 | 11/29/2024 | View on chart |
| ETR | ▲ Buy | Grant | 192 | $0 | 8/30/2024 | View on chart |
| ETR | ▲ Buy | Grant | 195 | $0 | 5/31/2024 | View on chart |
| ETR | ▲ Buy | Grant | 712 | $0 | 5/31/2024 | View on chart |
| ETR | ▲ Buy | Grant | 216 | $0 | 2/29/2024 | View on chart |
| ETR | ▲ Buy | Grant | 216 | $0 | 11/30/2023 | View on chart |
| ETR | ▲ Buy | Grant | 230 | $0 | 8/31/2023 | View on chart |
| ETR | ▲ Buy | Grant | 223 | $0 | 5/31/2023 | View on chart |
| ETR | ▲ Buy | Grant | 206 | $0 | 5/31/2023 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
FedEx eyes record-high Q4 delivery prices and expands digital pharma booking
FedEx expects delivery rates to reach record highs in the fourth quarter, according to a TD Cowen/AFS note. The company says its recent freight‑spin strategy has improved performance, though pricing is still relatively high. It also launched a digital booking platform for European cold‑chain pharmaceutical shipments to make the process smoother for customers.
FedEx eyes record-high Q4 delivery prices and expands digital pharma booking. FedEx expects delivery rates to reach record highs in the fourth quarter, according to a TD Cowen/AFS note. The company says its recent freight‑spin strategy has improved performance, though pricing is still relatively high. It also launched a digital booking platform for European cold‑chain pharmaceutical shipments to make the process smoother for customers.